Sino Biopharmaceutical Ltd (1177.HK)
Company Info
Highlights
HK$69.96B
35.55
3.11
HK$2.53 - HK$4.25
HK$4.63
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of HK$10,000 in Sino Biopharmaceutical Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Sino Biopharmaceutical Ltd (1177.HK) returned 20.50% year-to-date (YTD) and 36.12% over the past 12 months. Over the past 10 years, 1177.HK returned -7.22% annually, underperforming the S&P 500 benchmark at 10.43%.
1177.HK
20.50%
13.45%
10.54%
36.12%
-19.21%
-7.22%
^GSPC (Benchmark)
-3.70%
13.67%
-5.18%
9.18%
14.14%
10.43%
Monthly Returns
The table below presents the monthly returns of 1177.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -12.42% | 14.18% | 16.46% | 4.27% | -0.77% | 20.50% | |||||||
| 2024 | -19.02% | 11.39% | -3.51% | -10.60% | 5.18% | -4.94% | 5.24% | 14.94% | 16.60% | -5.36% | -7.93% | -0.92% | -5.26% |
| 2023 | -0.44% | -10.99% | 8.64% | -1.36% | -14.06% | -7.12% | 3.23% | -15.34% | -5.03% | 8.21% | 26.32% | -9.64% | -22.28% |
| 2022 | -1.83% | -7.09% | -1.81% | -15.13% | 6.27% | 13.81% | -8.65% | -8.81% | -9.51% | 3.25% | 20.21% | -0.22% | -14.19% |
| 2021 | -3.60% | 19.36% | -9.85% | 7.58% | 4.18% | -12.39% | -13.39% | -1.36% | -0.48% | -10.84% | -1.21% | -4.04% | -26.80% |
| 2020 | -4.40% | 8.25% | -9.40% | 10.96% | 7.58% | 19.79% | -30.82% | -11.39% | -5.48% | -7.35% | -0.26% | -3.56% | -30.77% |
| 2019 | 27.91% | 3.18% | 5.14% | 5.31% | 4.91% | 1.20% | 21.15% | 20.45% | -14.47% | 17.67% | -13.82% | 8.06% | 112.18% |
| 2018 | 4.04% | 2.77% | 3.91% | 8.44% | 18.80% | -39.27% | -10.96% | -7.28% | -26.45% | -3.70% | 1.56% | -27.60% | -62.62% |
| 2017 | 12.64% | 8.94% | -4.48% | 0.00% | 8.59% | -0.62% | 0.10% | -0.43% | 20.38% | 10.29% | 12.28% | 35.62% | 154.86% |
| 2016 | -24.93% | 7.36% | 2.28% | -5.15% | -4.53% | -3.92% | 2.58% | -3.86% | 4.75% | 4.22% | -2.03% | 2.76% | -22.26% |
| 2015 | 10.53% | -5.15% | 6.51% | 13.12% | 3.49% | -1.97% | -0.11% | 2.34% | 3.53% | 1.79% | -24.56% | -3.36% | 0.63% |
| 2014 | 6.99% | 9.57% | -8.32% | -8.17% | 4.12% | -0.47% | 6.21% | 7.05% | 8.32% | 1.04% | -1.79% | -8.29% | 14.63% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 80, 1177.HK is among the top 20% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Sino Biopharmaceutical Ltd (1177.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Sino Biopharmaceutical Ltd provided a 1.55% dividend yield over the last twelve months, with an annual payout of HK$0.06 per share.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | HK$0.06 | HK$0.06 | HK$0.08 | HK$0.10 | HK$0.04 | HK$0.05 | HK$0.04 | HK$0.04 | HK$0.03 | HK$0.03 | HK$0.02 | HK$0.02 |
Dividend yield | 1.55% | 1.86% | 2.31% | 2.19% | 0.73% | 0.71% | 0.37% | 0.77% | 0.22% | 0.49% | 0.25% | 0.27% |
Monthly Dividends
The table displays the monthly dividend distributions for Sino Biopharmaceutical Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | |||||||
| 2024 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.03 | HK$0.00 | HK$0.00 | HK$0.03 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.06 |
| 2023 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.06 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.02 | HK$0.00 | HK$0.00 | HK$0.08 |
| 2022 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.04 | HK$0.00 | HK$0.00 | HK$0.06 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.10 |
| 2021 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.02 | HK$0.00 | HK$0.00 | HK$0.02 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.04 |
| 2020 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.01 | HK$0.00 | HK$0.00 | HK$0.02 | HK$0.00 | HK$0.00 | HK$0.02 | HK$0.05 |
| 2019 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.01 | HK$0.00 | HK$0.00 | HK$0.01 | HK$0.00 | HK$0.00 | HK$0.01 | HK$0.04 |
| 2018 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.01 | HK$0.00 | HK$0.00 | HK$0.01 | HK$0.00 | HK$0.00 | HK$0.01 | HK$0.04 |
| 2017 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.01 | HK$0.01 | HK$0.00 | HK$0.01 | HK$0.00 | HK$0.01 | HK$0.00 | HK$0.03 |
| 2016 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.01 | HK$0.00 | HK$0.00 | HK$0.01 | HK$0.00 | HK$0.00 | HK$0.01 | HK$0.03 |
| 2015 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.01 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.02 |
| 2014 | HK$0.01 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.02 |
Dividend Yield & Payout
Dividend Yield
Sino Biopharmaceutical Ltd has a dividend yield of 1.55%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.
Payout Ratio
Sino Biopharmaceutical Ltd has a payout ratio of 52.42%, which is quite average when compared to the overall market. This suggests that Sino Biopharmaceutical Ltd strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Sino Biopharmaceutical Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Sino Biopharmaceutical Ltd was 87.72%, occurring on Apr 19, 2024. The portfolio has not yet recovered.
The current Sino Biopharmaceutical Ltd drawdown is 79.21%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -87.72% | May 29, 2018 | 1451 | Apr 19, 2024 | — | — | — |
| -81.11% | Apr 27, 2004 | 1064 | Oct 27, 2008 | 384 | May 14, 2010 | 1448 |
| -54.98% | Nov 9, 2015 | 155 | Jun 24, 2016 | 341 | Nov 10, 2017 | 496 |
| -52.11% | May 17, 2010 | 475 | Apr 17, 2012 | 165 | Dec 11, 2012 | 640 |
| -38.05% | Oct 3, 2000 | 4 | Oct 9, 2000 | 93 | Feb 28, 2001 | 97 |
Volatility
Volatility Chart
The current Sino Biopharmaceutical Ltd volatility is 18.75%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Sino Biopharmaceutical Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Sino Biopharmaceutical Ltd, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 63.3% positive surprise.
Valuation
The Valuation section provides an overview of how Sino Biopharmaceutical Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for 1177.HK, comparing it with other companies in the Biotechnology industry. Currently, 1177.HK has a P/E ratio of 35.5. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 1177.HK compared to other companies in the Biotechnology industry. 1177.HK currently has a PEG ratio of 3.1. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 1177.HK relative to other companies in the Biotechnology industry. Currently, 1177.HK has a P/S ratio of 2.4. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 1177.HK in comparison with other companies in the Biotechnology industry. Currently, 1177.HK has a P/B value of 2.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |